1 Min Read
March 24 (Reuters) - Neuren Pharmaceuticals
* Neuren’s Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric rett syndrome Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.